Verastem submits NDA to FDA for duvelisib

Verastem Inc. (NASDAQ:VSTM) submitted an NDA to FDA for duvelisib (IPI-145) to treat relapsed or refractory chronic lymphocytic

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE